Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: A chronic kidney disease markov model

Clinical Drug Investigation

Volumn 30, Issue 8, 2010, Pages 545-557

  Nuijten, Mark ^a   Andress, Dennis L ^b   Marx, Steven E ^b   Curry, Alistair S ^c   Sterz, Raimund ^b  

^a Ars Accessus Medica ^*  (Netherlands)

^b ABBOTT LABORATORIES   (United States)

^c ABBOTT LABORATORIES   (United Kingdom)

Author keywords

Alfacalcidol, therapeutic use; Calcitriol receptor agonists, therapeutic use, Cost effectiveness; Hyperparathyroidism, treatment; Kidney disorders, treatment; Paricalcitol, therapeutic use; Renal failure, treatment; Secondary hyperparathyroidism, treatment

Indexed keywords

ALFACALCIDOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PARICALCITOL; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR; ERGOCALCIFEROL; HYDROXYCOLECALCIFEROL;

ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; HUMAN; MORTALITY; PRIORITY JOURNAL; PROTEINURIA; QUALITY OF LIFE; SECONDARY HYPERPARATHYROIDISM; UNITED KINGDOM; CHRONIC DISEASE; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASE; PROBABILITY; QUALITY ADJUSTED LIFE YEAR;

CHRONIC DISEASE; COST-BENEFIT ANALYSIS; ERGOCALCIFEROLS; HUMANS; HYDROXYCHOLECALCIFEROLS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY DISEASES; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, CALCITRIOL;

EID: 77954181846     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11536310-000000000-00000     Document Type: Article

References (50)

1. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial 2004; 17: 209-216
2. Andress DL. Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation. Kidney Int 2006; 69: 33-43
3. Tsuchihashi K, Takizawa H, Torii T, et al. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: possible risk of vitamin D3 analog administration in dialysis patients with end-stage renal disease. Nephron 2000; 84: 13-20
4. Daisley-Kydd RE, Mason NA. Calcitriol in the management of secondary hyperparathyroidism of renal failure. Pharmacotherapy 1996; 16: 619-630
5. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121
6. Yudd M, Llach F. Current medical management of secondary hyperparathyroidism. Am J Med Sci 2000; 320: 100-106
7. Tuma SN, Martin RR, Mallette LE, et al. Augmented polymorphonuclear chemiluminescence in patients with secondary hyperparathyroidism. J Lab Clin Med 1981; 97: 291-298
8. Chervu I, Kiersztein M, Alexiewicz JM, et al. Impaired phagocytosis in chronic renal failure is mediated by secondary hyperparathyroidism. Kidney Int 1992; 41: 1501-1505
9. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997; 30: 606-620
10. Huraib S, Tanimu D, Romeh SA, et al. Effects of intravenous alfacalcidol on lymphocyte phenotyping in hemodialysis patients. Am J Kidney Dis 1998; 32: 1036-1040
11. Rubinger D, Friedlander MM, Silver J, et al. Progressive vascular calcification with necrosis of extremities in hemo-dialysis patients: a possible role of iron overload. Am J Kidney Dis 1986; VII: 125-129
12. Horl WH. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes. Nephrol Dial Transplant 2004; 19 Suppl. 5: V2-8
13. Warnock DG. Inclusion of albumin as a target in therapy guidelines: guidelines for chronic kidney disease. Kidney Int 2004; 92 Suppl.: S121-3
14. Llach F, Velasquez-Forero F. Secondary hyperparathyroidism in chronic renal failure: pathogenic and clinical aspects. Am J Kidney Dis 2001; 38 Suppl. 5: S20-33
15. National Kidney Foundation KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification [online]. Available from URL: http://www.kidney.org/professionals/KDOQI/guidelines- ckd/p4-class-g1.htm [Accessed 2010 May 11]
16. Slatopolsky E, Finch J, Ritter C, et al. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hy-percalcemia. Am J Kid Dis 1995; 26: 852-860
17. 2 on calcium and phosphorus resorption in bone. J Am Soc Nephrol 1999; 10: 980-985
18. Coyne DW, Grieff M, Ahya SN, et al. Differential effects of acute administration of 19-nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients. Am J Kidney Dis 2002; 40: 1283-1288
19. Martin KJ, Gonzales EA, Gellens M, et al. 19-Nor-1-a-25-dihydroxyvitamin D2 (paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432
20. Lindberg J, Martin KJ, Gonzalez EA, et al. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease. Clin Nephrol 2001; 56: 315-323
21. Sprague S, Llach F, Amdahl M, et al. Paricalcitol versus calcitriol in the treatment of secondary hyperpara-thyroidism. Kidney Int 2003; 63: 1483-1490
22. Llach F, Yudd M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am J Kidney Dis 2001; 38 Suppl. 5: S45-50
23. Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823-2828
24. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol Therapy. N Engl J Med 2003; 349: 446-456 (Pubitemid 36910023)
25. Dobrez D, Mathes A, Amdahl M, et al. Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical setting. Nephrol Dial Transplant 2004; 5: 1174-1181
26. Nuijten MJC. Cost-effectiveness of fluvoxamine in the treatment of recurrent depression in France. Pharmaco-economics 1998; 4: 433-455
27. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices-modeling studies. Value Health 2003; 6: 9-17
28. Barr J, Schumacher GE. Using decision analysis to conduct pharmacoeconomic studies. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven, 1996: 1197-1214
29. Sonnenberg F, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993; 13: 322-338
30. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089-2100
31. NICE Technology Appraisals No. 5 2001 guidance for manufacturers and sponsors [online]. Available from URL: http://www.nice.org.uk [Accessed 2006 May 1]
32. Roze S, Valentine J, Zakrzewska KE, et al. Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of type 1 diabetes in the UK. Diabetic Med 2005; 24: 1239-1245
33. Palmer AJ, Rodby RA. Health economics studies assessing irbesartan use in patients with hypertension, type 2 diabetes, and microalbuminuria. Kidney Int 2004; 92 Suppl.: S118-20
34. Stevenson M, Jones ML, De Nigris E, et al. A systematic review and economic evaluation of alendronate, eti-dronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 2005 Jun; 9 (22): 1-160
35. Roderick P, Nicholson T, Armitage A, et al. An evaluation of the costs, effectiveness and quality of renal replacement therapy provision in renal satellite units in England and Wales. Health Technol Assess 2005; 9: 1-178
36. Luengo-Fernandez R, Leal J, Gray A, et al. Cost of cardiovascular disease in the United Kingdom. Heart 2006; 92: 1384-1389
37. Personal Social Services Research Unit. Unit costs of health and social care 2003 [online]. Available from URL: http://www.pssru.ac.uk/pdf/uc2003/ uc2003-inflation.pdf [Accessed 2007 Apr 30]
38. Keith D, Nicholas G, Gullion C, et al. Mortality of chronic kidney disease in a large HMO population [abstract]. J Am Soc Nephrol 2002; 13: 620A
39. Nuijten M, Andress L, Marx S, et al. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin 2009; 25 (5): 1221-1234
40. Bakris GL, Levin A, Molitch M, et al. Disturbances of serum 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] in patients with chronic kidney disease [abstract]. J Am Soc Nephrol 2005; 16: 495A
41. Smith D, Gullion C, Nichols G, et al. Cost of medical care for CKD and comorbidity among enrollees in a large HMO population. J Am Soc Nephrol 2004; 15: 1300-1306
42. Schumock GT, Andress DL, Marx SE, et al. Impact of secondary hyperparathyroidism on disease progression, healthcare resource utilization and costs in predialysis CKD patients. Curr Med Res Opin 2008; 24 (11): 3037-3049
43. Kalantar-Zadeh K, Marx SE, Schumock G, et al. Examination of outcomes and costs of care among patients with chronic kidney disease and secondary hyperparathyroidism [abstract]. J Am Soc Nephrol 2006; 17: 647A
44. Dinneen S, Gerstein H. The association of microalbuminuria and mortality in non-insulin dependent diabetes mel-litus: a systematic overview of the literature. Arch Intern Med 1997; 157: 1413-1418
45. Boulware LE, Jaar BG, Tarver-Carr ME, et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290: 3101-3114
46. Gorodetskaya I, Zenios S, McCulloch CE, et al. Health-related quality of life and estimates of utility in chronic kidney disease. Kidney Int 2005; 68: 2801-2808
47. Hogan TJ, Elliott WJ, Seto AH, et al. Antihypertensive treatment with and without benazepril in patients with chronic renal insufficiency: a US economic evaluation. Pharmacoeconomics 2002; 20: 37-47
48. Smith DH, Johnson EJ, Thorp ML, et al. Hyperparathyroidism in chronic kidney disease: a retrospective cohort study of costs and outcomes. J Bone Miner Metab 2009; 27 (3): 287-294
49. Nuijten MJC. Data management in modelling studies: the selection of data sources. Pharmacoeconomics 1998; 3: 305-316
50. Fishbane S, Chittineni H, Packman M, et al. Oral paricalcitol in the Treatment of Patients with CKD and pro-teinuria: a randomized trial. Am J Kidney Dis 2009; 54 (4): 647-652